Given all the evidence above, regulating and intervening the enzymatic activity of cPLA2 by specific cPLA2 inhibitors and then promoting the normalization of downstream signals probably be considered as a promising alternative or supplement strategy to the current therapeutic methods for the treatment of RA. The gene discussed is PLA2G4A; the disease is rheumatoid arthritis.